Abstract
Objective Major depressive disorder (MDD) arises from a combination of genetic and environmental risk factors and DNA methylation is one of the molecular mechanisms through which these factors can manifest. However, little is known about the epigenetic signature of MDD in brain tissue. This study aimed to investigate associations between brain tissue-based DNA methylation and late-life MDD.
Methods We performed a brain epigenome-wide association study (EWAS) of late-life MDD in 608 participants from the Religious Order Study and the Rush Memory and Aging Project (ROS/MAP) using DNA methylation profiles of the dorsal lateral prefrontal cortex (dPFC) generated using the Illumina HumanMethylation450 Beadchip array. We also conducted an EWAS of MDD in each sex separately.
Results We found epigenome-wide significant associations between brain-tissue-based DNA methylation and late-life MDD. The most significant and robust association was found with altered methylation levels in the YOD1 locus (cg25594636, p-value=2.55 × 10−11; cg03899372, p-value=3.12 × 10−09; cg12796440, p-value=1.51 × 10−08, cg23982678, p-value=7.94 × 10−08). Analysis of differentially methylated regions (DMR, p-value=5.06 × 10−10) further confirmed this locus. Other significant loci include UGT8 (cg18921206, p-value=1.75 × 10−08), FNDC3B (cg20367479, p-value=4.97 × 10−08) and SLIT2 (cg10946669, p-value=8.01 × 10−08). Notably, brain-tissue based methylation levels were strongly associated with late-life MDD in men more than in women.
Conclusions We identified altered methylation in the YOD1, UGT8, FNDC3B and SLIT2 loci as new epigenetic factors associated with late-life MDD. Furthermore, our study highlights the sex-specific molecular heterogeneity of MDD.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
AH was supported by a research fellowship from the Deutsche Forschungsgemeinschaft (DFG; HU 2731/1-1) and by the HERCULES Center (NIEHS P30ES019776). MPE was supported by NIH grant R01 GM117946. APW is supported by NIH grants R01 AG056533, VA I01 BX003853, and NIH U01 MH115484. TSW was supported by NIH grants P50 AG025688, R56 AG062256, R56 AG060757, and R01 AG056533. CR was supported by NIH grant T32 NS007480. DAB was supported by P30AG10161, R01AG15819, R01AG17917, R01AG16042, R01AG36042, U01AG61356. The funders had no role in the study design, data collection and analysis, decision to publish, or preparation of manuscript.
Author Declarations
All relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.
Yes
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Funding: AH was supported by a research fellowship from the Deutsche Forschungsgemeinschaft (DFG; HU 2731/1-1) and by the HERCULES Center (NIEHS P30ES019776). MPE was supported by NIH grant R01 GM117946. APW is supported by NIH grants R01 AG056533, VA I01 BX003853, and NIH U01 MH115484. TSW was supported by NIH grants P50 AG025688, R56 AG062256, R56 AG060757, and R01 AG056533. CR was supported by NIH grant T32 NS007480. DAB was supported by P30AG10161, R01AG15819, R01AG17917, R01AG16042, R01AG36042, U01AG61356. The funders had no role in the study design, data collection and analysis, decision to publish, or preparation of manuscript.
Data Availability
If you are interested in using data or specimen from the Rush Alzheimer’s Disease Center (RADC), submit a request via RADC Research Resource Sharing Hub: www.radc.rush.edu.